Popular search terms:
Search Results
61 results found-
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/product-monograph-afluria-20232024-sep-5-2023.pdf -
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/product-monograph-afluria-2023-2024.pdf -
Higher Dose and Adjuvanted Influenza Vaccines for Persons 65yr+
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-fr/2022-references-fr.pdf -
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2023-pms/2023-fluad-product-monograph-12-apr-2023.pdf -
Higher Dose and Adjuvanted Influenza Vaccines for Persons 65yr+ https://www.cdc.gov/vaccines/acip/recs/grade/influenza-older-adults.html SREF-15734 14.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2022-references-en.pdf -
FLUCELVAX® QUAD Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures) Page 8 of 30 Percentages of Subjects with Any (Severe) Solicited Reactions3 18 to less than 65 years of age ≥ 65 years of age Trivalent Influenza Trivalent FLUCELVAX® FLUCELVAX® QUAD Vaccine Influenza Vaccine QUAD N=663 TIV1c TIV2c TIV1c TIV2c N=656 N=330 N=327 N=340 N=336 Fever:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2023-pms/2023-flucelvax-product-monograph-12-apr-2023.pdf -
Abbreviation Term AE Adverse event AEFI Adverse event following immunization ART Antiretroviral therapy CAEFISS Canadian Adverse Events Following Immunization Surveillance System CI Confidence interval CIG Canadian Immunization Guide DIN Drug Identification Number FFU Fluorescent focus units GBS Guillain-Barré syndrome GMT Geometric mean titre GMTR Geometric mean titre ratio HA Hemagglutinin HAART Highly active antiretroviral therapy HCW Health care worker HIV Human immunodeficiency virus Ig Immunoglobulin IIV Inactivated influenza vaccine IIV3 Trivalent inactivated influenza vaccine IIV3-Adj Adjuvanted trivalent inactivated influenza vaccine (egg-based) IIV3-HD High-dose trivalent inactivated influenza vaccine (egg-based) IIV3-SD Standard-dose trivalent inactivated influenza vaccine (egg-based) IIV4 Quadrivalent inactivated influenza vaccine Mammalian cell culture-based quadrivalent inactivated influenza IIV4-cc vaccine IIV4-HD High-dose quadrivalent inactivated influenza vaccine (egg-based) IIV4-SD Standard-dose quadrivalent inactivated influenza vaccine (egg-based) ILI Influenza-like illness
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/naci-2022-2023-statement.pdf -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Amongamong Healthcare Personnel Aged 18-64 Years:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-fr/naci-2022-2023-statement-fr.pdf -
CSL Seqirus commends the Government of Quebec for maintaining universal access to the influenza (flu) vaccine as part of the province’s Immunization Program for the 2023-24 flu season.
https://www.cslseqirus.ca/news/csl-seqirus-applauds-quebec-govt-decision-to-maintain-universal-influenza-immunization-program